Rui J. Wan

Key Laboratory Of Carcinogenesis And Translational Research
Beijing, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 76 publications

Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumors.

Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumors.

Journal: Drug delivery
Published: August 06, 2026

Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis.

Genomic Profiling, Risk Stratification, and Post-Transformation Treatment Outcomes in Patients with Transformed Small-Cell Lung Cancer: A Multicenter Analysis.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: May 05, 2026

A New Recruitable E3 Ligase UHRF1 Supporting Targeted Protein Degradation: A Minimal Azide as a Recruitment Ligand.

A New Recruitable E3 Ligase UHRF1 Supporting Targeted Protein Degradation: A Minimal Azide as a Recruitment Ligand.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 10, 2026

UFL1-Mediated UFMylation of ENO1 Restrains Aerobic Glycolysis and Colorectal Cancer Progression.

UFL1-Mediated UFMylation of ENO1 Restrains Aerobic Glycolysis and Colorectal Cancer Progression.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 06, 2026

Study on the Structural, Optical, and Magneto-Optical Properties of Bi2O3-Pb3(BO3)2-Ga2O3-PbO Glasses for Temperature-Insensitive Magneto-Optical Isolator Applications.

Study on the Structural, Optical, and Magneto-Optical Properties of Bi2O3-Pb3(BO3)2-Ga2O3-PbO Glasses for Temperature-Insensitive Magneto-Optical Isolator Applications.

Journal: Materials (Basel, Switzerland)
Published: September 15, 2025

Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial.

Safety and efficacy of YK-029A in previously treated EGFR T790M-Mutant NSCLC: A multi-center phase I trial.

Journal: Lung cancer (Amsterdam, Netherlands)
Published: July 18, 2025

UFMylation maintains tumor suppressor pVHL stability by activating the deubiquitinase BAP1.

UFMylation maintains tumor suppressor pVHL stability by activating the deubiquitinase BAP1.

Journal: Science advances
Published: July 11, 2025

UFMylation-dependent inhibition of AKT signaling by PHLDA3 in lung adenocarcinoma.

UFMylation-dependent inhibition of AKT signaling by PHLDA3 in lung adenocarcinoma.

Journal: Cell reports
Published: June 07, 2025

Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancer.

Structure-based classification for differential tyrosine kinase inhibitors efficacy of EGFR exon 19 deletions in non-small cell lung cancer.

Journal: Science China. Life sciences
Published: May 30, 2025

Phenotypic age acceleration and early-onset lung cancer: a case-control and prognostic cohort study involving multiple clinical centres with validation in the UK Biobank.

Phenotypic age acceleration and early-onset lung cancer: a case-control and prognostic cohort study involving multiple clinical centres with validation in the UK Biobank.

Journal: EBioMedicine
Published: April 16, 2025

Tumor-Informed ctDNA in Guiding First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancers.

Tumor-Informed ctDNA in Guiding First-Line Immunochemotherapy in Advanced Non-Small Cell Lung Cancers.

Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: April 15, 2025

HE-BiDet: A Hardware Efficient Binary Neural Network Accelerator for Object Detection in SAR Images.

HE-BiDet: A Hardware Efficient Binary Neural Network Accelerator for Object Detection in SAR Images.

Journal: Micromachines
Published: April 07, 2025
Showing 1-12 of 76

Last Updated: 09/26/2026